US EditionTrump Announces Cost Cuts to Weight Loss Drugs
The deal will cap Medicare co-pays at $50 and lower monthly drug prices to between $149 and $350, expanding access to millions of Americans, officials said.
- On Thursday, President Donald Trump unveiled a deal with Eli Lilly and Co. and Novo Nordisk to expand coverage and reduce prices for Zepbound and Wegovy, the White House said.
- Rising demand and high cost explain the move as GLP-1 receptor agonists surged in recent years but remained costly, limiting access for American patients, the White House said amid cost-of-living concerns.
- Through TrumpRx, uninsured consumers can buy obesity drugs at reduced prices, with Wegovy dropping to $250, Zepbound to $346, and starting doses at $149 if approved.
- Medicare will expand coverage starting next year, including a Part D pilot covering roughly 6.6 million beneficiaries, while state and federally funded Medicaid programs gain access to lower-priced obesity drugs.
- Experts warned of limits and restrictive eligibility as obesity experts noted state Medicaid variation, the White House tied the deals to MFN policy and tariff relief for three years, while Eli Lilly and Novo Nordisk will extend discounts to future oral GLP-1s.
531 Articles
531 Articles
GLP-1s Are A Miracle, Let’s Not Ruin It
By Stephen Kent via The Daily Signal | November 24, 2025 GLP-1s are helping Americans live better, but Washington has major work to do on safety. A lot has been happening this fall with the rocket ship rise of GLP-1 weight loss drugs. In September, the Food and Drug Administration announced a “green list” to stop the importation of counterfeit GLP-1 active pharmaceutical ingredients into the U.S., and then came news of Costco partnering with Nov…
GLP-1s Are a Miracle, Let’s Not Ruin It
GLP-1s are helping Americans live better, but Washington has major work to do on safety. A lot has been happening this fall with the rocket ship rise of GLP-1 weight loss drugs. In September, the Food and Drug Administration announced a “green list” to stop the importation of counterfeit GLP-1 active pharmaceutical ingredients into the U.S., and then came news of Costco partnering with Novo Nordisk on a discount for uninsured members of the popu…
Could Trump do for Branded Expensive Drugs What He Just Did for GLP
The Trump administration’s new deal lowers prices and expands access to GLP-1 drugs, but experts argue far broader reforms are needed to address high prescription drug costs overall. The post Could Trump do for Branded Expensive Drugs What He Just Did for GLP-1s? appeared first on MedCity News.
Medicare to cover obesity drugs under Trump deal for as little as $50
The White House recently announced a landmark deal with pharmaceutical companies Eli Lilly and Nordisk that will impact Medicare beneficiaries and others in the coming months. The agreement cuts prices for GLP-1 receptor agonists, such as Ozempic ...
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
